Valion Bio Leadership Change
Lisa Wolf has voluntarily resigned from her positions as President, Chief Operating Officer, and Chief Financial Officer of Valion Bio, Inc. Her resignation is scheduled to become effective on December 11, 2026.
ALFA USA Filings
Every alert, straight from SEC EDGAR
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Valion Bio, Inc. filings on SEC EDGAR ↗
Filing type
Alerts
Time
4 alerts with these filters
Lisa Wolf has voluntarily resigned from her positions as President, Chief Operating Officer, and Chief Financial Officer of Valion Bio, Inc. Her resignation is scheduled to become effective on December 11, 2026.
Valion Bio, Inc. terminated the employment of Melinda Lackey, General Counsel and Senior Vice President of Legal Affairs, effective October 30, 2026. Under a separation agreement, she will receive a lump-sum cash severance payment of $26,750 and temporary COBRA premium coverage.
Valion Bio issued a press release highlighting the appointment and strategic goals of its new Board Chair, Thomas Jensen, who joined the board in September 2026. Jensen, the current CEO of Allarity Therapeutics, will focus on advancing the company's lead candidate, Entolimod, as a medical countermeasure for acute radiation syndrome. The company is leveraging Jensen's experience in biotech turnarounds to align strategic priorities with disciplined resource allocation.
Valion Bio, Inc. appointed Dean Zikria as Interim Chief Executive Officer, effective September 22, 2026, succeeding Sheryle Bolton who stepped down from the Board. Mr. Zikria, an existing director, will receive a monthly consulting fee of $23,333 and up to 100,000 restricted stock units as part of his interim leadership agreement.